Renal Prostaglandins and Sodium Balance in the Rabbit: Lack of Effect of Aspirin-like Drugs

ABSTRACT Variations in plasma renin activity and urinary aldosterone excretion were studied in normal subjects submitted to salt restriction and simultaneous inhibition of ACTH production with a new synthetic steroid, 6-dehydro-16-methylene hydrocortisone (STC 407). At a dose of 10 mg t. i. d. this preparation exerts an inhibitory effect on the pituitary comparable to that of 2 mg of dexamethasone. In subjects maintained on a restricted salt intake, STC 407 does not delay the establishment of an equilibrium in sodium balance. The increases in endogenous aldosterone production and in plasma renin activity are also similar to those seen in the control subjects. A possible mineralocorticoid effect of STC 407 can be excluded. Under identical experimental conditions, the administration of dexamethasone yielded results comparable to those obtained with STC 407.

Download Full-text

Neuronal nitric oxide synthase and systemic vasodilation in rats with cirrhosis

AJP Renal Physiology ◽

10.1152/ajprenal.2000.279.6.f1110 ◽

2000 ◽

Vol 279 (6) ◽

pp. F1110-F1115 ◽

Cited By ~ 50

Author(s):

Lieming Xu ◽

Ethan P. Carter ◽

Mamiko Ohara ◽

Pierre-Yves Martin ◽

Boris Rogachev ◽

...

Keyword(s):

Nitric Oxide ◽

Liver Cirrhosis ◽

Nitric Oxide Synthase ◽

Control Treatment ◽

Sodium Balance ◽

Hyperdynamic Circulation ◽

Molecular Approaches ◽

Advanced Liver Cirrhosis ◽

Oxide Synthase

Cirrhosis is typically associated with a hyperdynamic circulation consisting of low blood pressure, low systemic vascular resistance (SVR), and high cardiac output. We have recently reported that nonspecific inhibition of nitric oxide synthase (NOS) with nitro-l-arginine methyl ester reverses the hyperdynamic circulation in rats with advanced liver cirrhosis induced by carbon tetrachloride (CCl4). Although an important role for endothelial NOS (eNOS) is documented in cirrhosis, the role of neuronal NOS (nNOS) has not been investigated. The present study was carried out to specifically investigate the role of nNOS during liver cirrhosis. Specifically, physiological, biochemical, and molecular approaches were employed to evaluate the contribution of nNOS to the cirrhosis-related hyperdynamic circulation in CCl4-induced cirrhotic rats with ascites. Cirrhotic animals had a significant increase in water and sodium retention. In the aorta from cirrhotic animals, both nNOS protein expression and cGMP concentration were significantly elevated compared with control. Treatment of cirrhotic rats for 7 days with the specific nNOS inhibitor 7-nitroindazole (7-NI) normalized the low SVR and mean arterial pressure, elevated cardiac index, and reversed the positive sodium balance. Increased plasma arginine vasopressin concentrations in the cirrhotic animals were also repressed with 7-NI in association with diminished water retention. The circulatory changes were associated with a reduction in aortic nNOS expression and cGMP. However, 7-NI treatment did not restore renal function in cirrhotic rats (creatinine clearance: 0.76 ± 0.03 ml · min−1· 100 g body wt−1in cirrhotic rats vs. 0.79 ± 0.05 ml · min−1· 100 g body wt−1in cirrhotic rats+7-NI; P NS.). Taken together, these results indicate that nNOS-derived NO contributes to the development of the hyperdynamic circulation and fluid retention in cirrhosis.

Download Full-text

Regulation of Serum Sodium Levels during Chemotherapy Using Selective Arginine Vasopressin V2-Receptor Antagonist Tolvaptan in a Four-Year-Old Girl with a Suprasellar Germ Cell Tumor

Children ◽

10.3390/children8040293 ◽

2021 ◽

Vol 8 (4) ◽

pp. 293

Author(s):

Shota Hiroshima ◽

Hiromi Nyuzuki ◽

Sunao Sasaki ◽

Yohei Ogawa ◽

Keisuke Nagasaki

Keyword(s):

Germ Cell ◽

Germ Cell Tumor ◽

Serum Sodium ◽

Hormone Secretion ◽

Urine Volume ◽

Cell Tumor ◽

Sodium Balance ◽

Infusion Therapy ◽

Inappropriate Antidiuretic Hormone Secretion ◽

Control Serum

There are limited reports on the use of tolvaptan for syndrome of inappropriate antidiuretic hormone secretion (SIADH) in children. Managing serum sodium levels in SIADH patients during chemotherapy is often difficult because of the need for massive fluid infusions. We report the course of the use of tolvaptan for the treatment of hyponatremia during chemotherapy in a four-year-old girl with a suprasellar germ cell tumor. The patient was a Japanese girl who presented with left ptosis with a mass in the pituitary gland and cavernous sinus. She was diagnosed with an intermediate-grade germ cell tumor and was treated with carboplatin and etoposide combination chemotherapy. She developed hyponatremia due to SIADH caused by intravenous infusion therapy before chemotherapy. Subsequently, tolvaptan (3.25 mg; 0.20 mg/kg/dose) was administered orally to control serum sodium levels. After 4 h of administration, a marked increase in urine volume of up to 15 mL/kg/h was observed, and serum sodium level increased from 126 to 138 mEq/L after 10 h of tolvaptan administration, followed by a decrease in urine volume. The use of tolvaptan in pediatric patients with SIADH who require intravenous hydration during chemotherapy can be useful for the management of serum sodium balance.

Download Full-text

Issues and Controversies in the Evolution of Oral Rehydration Therapy (ORT)

Tropical Medicine and Infectious Disease ◽

10.3390/tropicalmed6010034 ◽

2021 ◽

Vol 6 (1) ◽

pp. 34

Author(s):

David Nalin

Keyword(s):

Pediatric Patients ◽

Oral Rehydration Therapy ◽

Sodium Balance ◽

Plain Water ◽

Oral Glucose ◽

Oral Rehydration ◽

Low Sodium ◽

Current Review ◽

The Subject ◽

Rehydration Solution

The original studies demonstrating the efficacy of oral glucose-electrolytes solutions in reducing or eliminating the need for intravenous therapy to correct dehydration caused by acute watery diarrheas (AWD) were focused chiefly on cholera patients. Later research adapted the oral therapy (ORT) methodology for treatment of non-cholera AWDs including for pediatric patients. These adaptations included the 2:1 regimen using 2 parts of the original WHO oral rehydration solution (ORS) formulation followed by 1 part additional plain water, and a “low sodium” packet formulation with similar average electrolyte and glucose concentrations when dissolved in the recommended volume of water. The programmatic desire for a single ORS packet formulation has led to controversy over use of the “low sodium” formulations to treat cholera patients. This is the subject of the current review, with the conclusion that use of the low-sodium ORS to treat cholera patients leads to negative sodium balance, leading to hyponatremia and, in severe cases, particularly in pediatric cholera, to seizures and other complications of sodium depletion. Therefore it is recommended that two separate ORS packet formulations be used, one for cholera therapy and the other for non-cholera pediatric AWD.

Download Full-text

Increased oxytocin release precedes hyponatremia after pituitary surgery

Pituitary ◽

10.1007/s11102-020-01121-4 ◽

2021 ◽

Author(s):

Paul Eugène Constanthin ◽

Nathalie Isidor ◽

Sophie de Seigneux ◽

Shahan Momjian

Keyword(s):

Transsphenoidal Surgery ◽

Pituitary Surgery ◽

Sodium Balance ◽

Posterior Pituitary ◽

Axon Terminals ◽

Early Marker ◽

Inappropriate Secretion ◽

Oxytocin Release ◽

Transsphenoidal Pituitary Surgery ◽

First Time

Abstract Purpose The syndrome of inappropriate secretion of antidiuretic hormone (SIADH) is a well-known complication of transsphenoidal pituitary surgery, related to inappropriate secretion of arginine vasopressin (AVP). Its diagnosis is based on hyponatremia, with a peak of occurrence around day 7 after surgery and, to date, no early marker has been reported. In particular, copeptin levels are not predictive of hyponatremia in this case. Oxytocin (OXT) is secreted into the peripheral blood by axon terminals adjacent to those of AVP neurons in the posterior pituitary. Besides its role in childbirth and lactation, recent evidences suggested a role for OXT in sodium balance. The contribution of this hormone in the dysnatremias observed after pituitary surgery has however never been investigated. Methods We analyzed the urinary output of OXT in patients subjected to transsphenoidal pituitary surgery. Results While OXT excretion remained stable in patients who presented a normonatremic postoperative course, patients who were later diagnosed with SIADH-related hyponatremia presented with a significantly increased urinary secretion of OXT 4 days after surgery. Conclusion Taken together, these results show for the first time that urinary OXT output remains normally stable after transsphenoidal pituitary surgery. OXT excretion however becomes abnormally high on or around 4 days after surgery in patients later developing hyponatremia, suggesting that this abnormal dynamics of OXT secretion might serve as an early marker for transsphenoidal surgery-related hyponatremia attributed to SIADH.

Download Full-text

Effects of Physiological Increments in Human α-Atrial Natriuretic Peptide and Human Brain Natriuretic Peptide in Normal Male Subjects

Clinical Science ◽

10.1042/cs0860723 ◽

1994 ◽

Vol 86 (6) ◽

pp. 723-730 ◽

Cited By ~ 22

Author(s):

B. M. Y. Cheung ◽

J. E. C. Dickerson ◽

M. J. Ashby ◽

M. J. Brown ◽

J. Brown

Keyword(s):

Atrial Natriuretic Peptide ◽

Human Brain ◽

Brain Natriuretic Peptide ◽

Natriuretic Peptide ◽

Physiological Role ◽

Sodium Balance ◽

Urinary Flow ◽

Male Subjects ◽

The Brain ◽

Atrial Natriuretic

1. Brain natriuretic peptide, closely related to atrial natriuretic peptide in structure, may be an important circulating hormone. Its physiological role is unclear. First, we studied the effects of incremental infusions of brain natriuretic peptide in six healthy men on plasma brain natriuretic peptide levels and the pharmacokinetics of brain natriuretic peptide. Synthetic human brain natriuretic peptide-32 was infused intravenously, at an initial rate of 0.4 pmol min−1 kg−1, doubling every 15 min until the dose rate reached 6.4 pmol min−1 kg−1, at which rate the infusion was maintained for 30 min. 2. The brain natriuretic peptide infusion raised the brain natriuretic peptide-like immunoreactivity from 1.4 ± 0.5 pmol/l to 21.4 ± 7.6 pmol/l. Brain natriuretic peptide-like immunoreactivity after the end of infusion was consistent with a bi-exponential decay, with half-lives of 2.1 min and 37 min. 3. Next, we studied the effects of low-dose infusion of brain natriuretic peptide to mimic physiological increments in the circulating levels in comparison with atrial natriuretic peptide. Six dehydrated male subjects received intravenous infusions of atrial natriuretic peptide and brain natriuretic peptide, separately and in combination, in a randomized double-blind, placebo-controlled, four-part cross-over design. Atrial natriuretic peptide and brain natriuretic peptide were given at the rate of 0.75 and 0.4 pmol min−1 kg−1, respectively, for 3 h. The control infusion consisted of the vehicle. 4. Analysis of variance showed that atrial natriuretic peptide and atrial natriuretic peptide plus brain natriuretic peptide, but not brain natriuretic peptide alone, increased urinary flow and decreased urinary osmolality significantly. However, urinary sodium excretion was significantly increased by atrial natriuretic peptide, brain natriuretic peptide and atrial natriuretic peptide plus brain natriuretic peptide. 5. None of the four infusates significantly altered the blood pressure, heart rate or glomerular filtration rate. 6. This study showed, for the first time, that physiological increments in brain natriuretic peptide, like those in atrial natriuretic peptide, are natriuretic. Although atrial natriuretic peptide and brain natriuretic peptide do not appear to interact synergistically, they are likely to act in concert in the physiological regulation of sodium balance.

Download Full-text

Role of Endogenous Endothelin in Renal Function During Altered Sodium Balance

Journal of Cardiovascular Pharmacology ◽

10.1097/00005344-199100177-00082 ◽

1991 ◽

Vol 17 ◽

pp. S290-292 ◽

Cited By ~ 1

Author(s):

Kenichi Yamada ◽

Sho Yoshida

Keyword(s):

Renal Function ◽

Sodium Balance

Download Full-text